Intended for UK Healthcare Professionals Adverse event reporting can be found at the bottom of the page

Resources & Downloads

Supporting materials for healthcare professionals and patients

Healthcare Professional Resources

Clinical and prescribing resources to support your practice

Prescribing Information

Full prescribing information including indications, contraindications, warnings, and dosing.

Download PDF

CLARITY-1 Clinical Summary

Summary of efficacy and safety data from the Phase III CLARITY-1 trial.

Download PDF

Mechanism of Action Animation

Video explaining how DEMOZUMAB works to address CFR-1 receptor dysregulation.

Watch Video

Dosing Quick Reference

Single-page dosing guide for quick reference during consultations.

Download PDF

Patient Resources

Materials to support your patients starting DEMOZUMAB

Patient Information Leaflet

Comprehensive guide for patients about DEMOZUMAB treatment.

Download

Injection Training Guide

Step-by-step instructions for self-administering DEMOZUMAB.

Download

Appointment Reminder Card

Wallet card for tracking injection dates and appointments.

Download

Request Materials or Support

Order Printed Materials

Request printed copies of patient and HCP resources for your practice.

Order Now

Request a Rep Visit

Schedule a visit from a Siguru Pharmaceuticals representative.

Request Visit

Medical Information

Contact our medical information team with clinical questions.

Contact Us

CLARITY Patient Support Programme

Our dedicated patient support programme provides comprehensive assistance for patients starting DEMOZUMAB treatment.

Programme Benefits

  • Injection training and ongoing support
  • Dedicated patient support line
  • Appointment and dosing reminders
  • Educational materials and resources
  • Connection with specialist nurses
Learn More About Patient Support
[Patient Support Image Placeholder]

References

  1. DEMOZUMAB (vigilanafine) Summary of Product Characteristics. Siguru Pharmaceuticals. January 2025.
  2. Harrison M, et al. Efficacy and safety of vigilanafine in adults with moderate-to-severe Cumulative Detail Fatigue: Results from the CLARITY-1 Phase III trial. J Cognitive Precision Med. 2024;12(4):234-251.
  3. Thompson K, et al. Long-term outcomes in patients with CDF: 24-week data from CLARITY-1. Cognitive Neurol. 2024;8(2):112-128.
  4. Chen W, et al. Mechanism of action of CFR-1 inhibition in cognitive fatigue disorders. Neuropharmacology. 2023;45(3):78-92.
  5. Data on file. Siguru Pharmaceuticals. REF-2025-001.